Steroid-induced diabetes in oncology
Journal Title: OncoReview - Year 2012, Vol 2, Issue 2
Abstract
Patients with neoplasms belong to the group of higher risk for developing steroid-induced diabetes. The rules of diagnosis of this form of diabetes do not differ from others of its type, but the course and treatment differ significantly from the clinical picture observed in type 1 and 2. It results from different schemes of glicocorticotherapy, differentiated state of the patient dependent on tumor stage and presence of comorbidities. However, note that in a patient with hyperplastic process, diabetes can occur regardless of the administration of diabetogenic agents, which can be exemplified by the presence of diabetes or pre-diabetic status in a patient with pancreatic cancer. Another clinical situation occurs if the patient with diabetes has to be treated with glicocorticosteroids due to neoplasmatic process. It should be emphasized as an inverse relationship eg. stimulation of tumor growth by processes occurring in type 2 diabetes particularly with concomitant visceral obesity. Such a patient will be more prone to induce hyperglycaemia during glicocorticotherapy. The atricle presents the practical aspects of treatment of hyperglycemia in glicocorticotherapy.
Authors and Affiliations
Beata Mrozikiewicz-Rakowska
Keywords
Related Articles
- EP ID EP53155
- DOI -
- Views 224
- Downloads 0
Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors....
Imaging techniques used to detect oncological treatment complications
Oncological drugs are toxic for the cardiovascular system, directly affecting cardiac function and anatomy. Oncological treatment complications may thus take the form of asymptomatic myocardial dysfunction, overt heart f...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...
Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. Advances in the understanding of the molecular mechanisms of GIST pathogenesis have resulted for last years in the...
Superior efficacy of nilotinib vs imatinib in patients with chronic myeloid leukemia in chronic phase. ENESTnd and ENESTcmr current results analysis
Second generation tyrosine kinase inhibitors can improve the efficacy of treatment and outcome in newly diagnosed patients with chronic myeloid leukemia in chronic phase. The primary endpoint of ENESTnd trial is the comp...